Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 0.2660 -0.0006 (-0.23%) Official Closing Price Updated: 8:00 PM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Cybin Inc < Previous 1 2 3 4 5 6 7 8 9 ... 20 21 Next > CYBN Stock Earnings: Cybin Beats EPS for Q1 2024 August 09, 2024 CYBN stock results show that Cybin beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves July 31, 2024 Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. Via Benzinga 3 Biotech Stocks That Could Make Your Summer Unforgettable July 30, 2024 If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider. Via InvestorPlace Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns July 03, 2024 Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks. Via InvestorPlace 3 Psychedelic Stocks to Buy on the Dip: Summer 2024 July 02, 2024 These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns. Via InvestorPlace CYBN Stock Earnings: Cybin Beats EPS for Q4 2023 June 26, 2024 CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss February 16, 2024 The TDR Three Key Takeaways: Via Benzinga Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development June 26, 2024 Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now! Via Benzinga Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More June 18, 2024 As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics... Via Benzinga Topics Cannabis Exposures Cannabis Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment June 05, 2024 FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. Via Benzinga Exposures Product Safety Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon May 09, 2024 Via Benzinga Topics Cannabis Exposures Cannabis Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More March 30, 2024 Via Benzinga 3 Penny Stocks That Could Be Multibaggers in the Making: March Edition March 26, 2024 Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. Via InvestorPlace Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More March 20, 2024 Via Benzinga Topics Economy Exposures Interest Rates FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement March 13, 2024 Via Benzinga Exposures Product Safety 3 High-Potential Penny Stocks to Turn $1000 into $1 million March 10, 2024 U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices. Via InvestorPlace Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More March 04, 2024 Via Benzinga Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More February 15, 2024 Via Benzinga Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More January 27, 2024 New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... Via Benzinga FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety January 23, 2024 Cybin will advance the clinical development of the novel psychedelic molecule CYB004 for generalized anxiety treatment. Via Benzinga Exposures Product Safety Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More January 15, 2024 Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024. Via Benzinga Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More January 12, 2024 Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD Via Benzinga 30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond January 10, 2024 The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health... Via Benzinga Cybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical Results January 09, 2024 Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and... Via Benzinga Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD January 06, 2024 A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub Via Benzinga Psychedelic Stock Gainers And Losers From January 1, 2024 January 01, 2024 Via Benzinga Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential December 14, 2023 The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. Via InvestorPlace Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More December 05, 2023 Defense Dept. Funds Ketamine Study For PTSD Treatment Via Benzinga Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next? December 03, 2023 Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a... Via Benzinga Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More November 24, 2023 GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Via Benzinga Topics Cannabis Exposures Cannabis < Previous 1 2 3 4 5 6 7 8 9 ... 20 21 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.